UK markets closed

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
9.91+0.23 (+2.38%)
At close: 4:00PM EDT

Aerie Pharmaceuticals, Inc.

4301 Emperor Boulevard
Suite 400
Durham, NC 27703
United States
919 237 5300
http://www.aeriepharma.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees380

Key executives

NameTitlePayExercisedYear born
Dr. Vicente J. Anido Jr.CEO & Chairman1.13MN/A1953
Mr. Thomas A. MitroPres & COO582.78kN/A1958
Dr. Casey C. KopczynskiCo-Founder & Chief Scientific Officer582.51k2.2M1961
Mr. Richard James Rubino CPACFO, Sec. & Treasurer620.37kN/A1958
Mr. John W. LaRocca Esq.Gen. Counsel & Assistant Sec.576.3kN/A1966
Mr. Jeffrey CalabreseDirector of AccountingN/AN/AN/A
Ms. Ami BavishiDirector of Investor RelationsN/AN/AN/A
Ms. Charlene E DavisVP & Chief Compliance OfficerN/AN/AN/A
Mr. Tad HeitmannHead of CommunicationsN/AN/AN/A
Ms. Deanne F. MelloyVP of MarketingN/AN/A1968
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Corporate governance

Aerie Pharmaceuticals, Inc.’s ISS governance QualityScore as of 6 October 2020 is 7. The pillar scores are Audit: 1; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.